Brought to you by 
Neuro3d licenses anti-psychotic from Janssen
13 Feb 2003
Executive Summary
Neuro3d SA (year 2000 start-up; combines internal research with in-licensing) has negotiated exclusive worldwide rights from J&J's Janssen Pharmaceutica NV business to its ocaperidone anti-psychotic compound.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neuro3d licenses anti-psychotic from Janssen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice